Rockwell Medical (RMTI) : The highest short term price target forecast on Rockwell Medical (RMTI) is $7 and the lowest target price is $3. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $4.33 with a standard deviation of $2.31.
Rockwell Medical (RMTI) : 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Rockwell Medical (RMTI). Zacks Investment Research suggests a Hold with a rank of 3. 2 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 4 Wall Street Analysts endorse the stock as a Sell with a rating of 3.83.
Also, BTIG Research initiates coverage on Rockwell Medical (NASDAQ:RMTI). The rating major has initiated the coverage with buy rating on the shares. The Analysts at BTIG Research announces a current price target of $12 per share. The rating by the firm was issued on August 19, 2016.
Rockwell Medical (NASDAQ:RMTI): The stock opened at $7.25 on Thursday but the bulls could not build on the opening and the stock topped out at $7.33 for the day. The stock traded down to $7.11 during the day, due to lack of any buying support eventually closed down at $7.22 with a loss of -0.55% for the day. The stock had closed at $7.26 on the previous day. The total traded volume was 167,114 shares.
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Companys lead branded drug, Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwells generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.